GSK, Zofran Users Bicker Over Scope Of Patient Discovery

By Alison Noon (April 25, 2018, 7:56 PM EDT) -- Counsel for GlaxoSmithKline and families who claim its anti-nausea medication Zofran caused various birth defects argued in Boston federal court Wednesday over how many patients should be targeted for individual discovery in the multidistrict product liability litigation.

The pharmaceutical giant proposed questioning 240 people, or more than half of the roughly 425 patients whose cases have been consolidated in Massachusetts, while the families said subjecting eight people to discovery should be more than enough to identify potential bellwether cases. The families claim GSK knowingly and wrongfully asked prescribers to give pregnant patients Zofran off-label to treat morning sickness.

Tobias Millrood of Pogust Braslow...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!